ClinicalTrials.gg
WithdrawnNCT06407999Updated Nov 7, 2024

Pressure Relief Algorithm Eval

An interventional study of Expiratory Pressure Relief in Obstructive Sleep Apnea, sponsored by SleepRes Inc.. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-07.

Sponsored by SleepRes Inc. · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Funds were redirected to other projects with higher priority

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 755 studies in Sleep Apnea, Obstructive with a site in United States — 127 open to participants now, 162 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
552nd of 596
0 · median 49
Started
2025
with 32 others
No phase
412 of 755
68 open now
Registered
665th of 755
by date

Among the 755 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 552nd largest by enrollment of the 596 interventional ones that give a count, is one of 33 that started in 2025, is one of 412 with no phase, and was the 665th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

127 of the 755 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

122 more — sign in →

All 127 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 755 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

The PRA Effect on APAP Therapy Pressure Study is a randomized, controlled, crossover study in PAP-adherent participants with OSA. Pre-screening is conducted to establish potential eligibility based on regular usage of > 4 hours/night on patients who use an APAP device with a PRA mode. Participants would then be recruited as described below. For those who sign an informed consent, they will be instructed to use the device for the next 8 days with the PRA turned on for four consecutive nights and off for four consecutive nights, but in random orientation. To make sure that the device is not limited to APAP range when adjusting to respond to PRA, the upper limit will be changed to 20 cmH2O during the study. Additionally, only patients who have a current P95 of 8 cmH2O or greater will be eligible so that the maximum PRA setting of 3 cmH2O can be used.

Read the detailed description

The first phase of recruiting for the PRA Effect on APAP Therapy Pressure Study will be done during a single phone contact following an email recruitment. During this call, participants will be explained the study along with risks and benefits and evaluated for inclusion and exclusion criteria. If the participant is eligible to enter the study, they will be sent an electronic Informed Consent Form to sign. Once the form is signed and verified, the study can then start that evening, after the participant's device has been set for the study.

During both arms of the study, every aspect of operation of the APAP devices will be the same as those the patient normally uses, except for the following three things:

  • APAP upper range limit will be set to 20 cmH2O
  • PRA or 3 cmH2O will be either on or off
  • Participants cannot use a V̇-Com™ device. Participants will randomly be assigned to start with or without PRA. Once the settings are remotely assigned to the device, the patient will sleep on these settings for four nights, ideally consecutively.

After four nights, the PRA setting will be remotely switched to the 2nd arm setting (on or off), and median and P95 pressure, Usage, AHI, and Leak averaged over those four nights will be downloaded. The participant will then use the device with the new settings for an additional four nights, hopefully also sequentially.

Following the 2nd group of four nights, median and P95 pressure, Usage, AHI, and Leak averaged over those four nights will be downloaded, the participant will be informed that their involvement in the study is complete, and the device will be remotely set back to the settings it had prior to the study. Participants will then receive the compensation credit.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adherent use of ≥ four hours/night over previous 2 months.
  2. P95 ≥ 8 cmH2O.

Exclusion criteria

Exclusion Criteria:

  1. Excessive alcohol consumption (>14 drinks/week).
  2. The use of any illegal drug(s).
  3. Any condition that in the investigator's opinion would present an unreasonable risk to the participant, or which would interfere with their participation in the study or confound study interpretation.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    APAP w/ EPR On

    The patient will use their normal CPAP device and equipment in the normal operating mode but we will set EPR on if they do not already use it that way.

    Device: Expiratory Pressure Relief

  • Placebo comparator
    APAP w/ EPR Off

    The patient will use their normal CPAP device and equipment in the normal operating mode but we will set EPR off if they do not already use it that way.

    Device: Expiratory Pressure Relief

Interventions

  • DeviceExpiratory Pressure Relief

    EPR is a function used in CPAP intended to improve comfort by reducing delivered pressure during the expiratory phase. When EPR is not used, the patient receives true CPAP.

    Also known as: C-Flex, EPR

06

What researchers measure

Primary outcomes

  1. P95/P90

    P95/P90 represent pressure levels that eliminate breathing obstructions for at least 90% to 95% of the sleep period

    Time frame: Averaged over every night for each 4-night arm

Secondary outcomes

  1. Leak

    Leak measured by the device in excess of the required exhaust valve leak to purge CO2 from the breathing circuit.

    Time frame: Averaged over every night for each 4-night arm

  2. Usage

    Elapsed therapy usage time measured each night

    Time frame: Averaged over every night for each 4-night arm

  3. AHI

    Apnea/Hypopnea Index - Measurement of obstructive events averaged over the night in events per hour.

    Time frame: Averaged over every night for each 4-night arm

07

Study locations

1 site
  • Sleep Centers of Middle Tennessee
    Murfreesboro, Tennessee 37129, United States
08

References and documents

Individual participant data

Plan to share: No — Only plan to publish results.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
May 9, 2024
StartEst.
Jan 1, 2025
Primary completionEst.
Dec 1, 2025
CompletionEst.
Jan 1, 2026
Last update
Nov 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06407999
Lead sponsor
SleepRes Inc.
Responsible party
Sponsor
First posted
May 9, 2024
Start date
Jan 1, 2025 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Jan 1, 2026 (estimated)
Last update
Nov 7, 2024

Study contacts

William H Noah, MD
study director · SleepRes, LLC., Sleep Centers of Middle Tennessee, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion